Cangene Corporation clinical trials
Acquired by Emergent BioSolutions, Feb 21, 2014 · source ↗
The registry lists 3 studies whose lead sponsor is Cangene Corporation. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 23, 2016.
Before and after it joined Emergent BioSolutions
- First submitted before Cangene Corporation became part of Emergent BioSolutions
- 3
- First submitted after Cangene Corporation became part of Emergent BioSolutions
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Approved for marketing
- 1
- Withdrawn
- 1
- Completed
- 1
Registry sponsor names on this page
- Cangene Corporation3 studies
Something wrong with this grouping? Tell us on the Emergent BioSolutions page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Emergent BioSolutions studies →
- Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia BWithdrawnNCT02048111Phase 3
Sponsor listed in the registry: Cangene Corporation · First submitted before Cangene Corporation became part of Emergent BioSolutions
- Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant PatientsCompletedNCT00722332Phase 4
Sponsor listed in the registry: Cangene Corporation · First submitted before Cangene Corporation became part of Emergent BioSolutions
- Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella InfectionApproved for marketingNCT00338442
Sponsor listed in the registry: Cangene Corporation · First submitted before Cangene Corporation became part of Emergent BioSolutions